MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
暂无分享,去创建一个
C. Croce | G. Calin | M. Negrini | L. Bolondi | G. Grazi | P. Chieco | L. Gramantieri | F. Fornari | M. Milazzo | Daniela Pollutri
[1] Zhiming Wang,et al. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma , 2010, Medical oncology.
[2] C. Croce,et al. MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Dolganiuc,et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. , 2009, Alcoholism, clinical and experimental research.
[4] M. Manns,et al. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage , 2009, Hepatology.
[5] G. Tsujimoto,et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer , 2009, International journal of cancer.
[6] S. Giulini,et al. MicroRNA‐23b mediates urokinase and c‐met downmodulation and a decreased migration of human hepatocellular carcinoma cells , 2009, The FEBS journal.
[7] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Yi Luan,et al. miR-199a*, a Bone Morphogenic Protein 2-responsive MicroRNA, Regulates Chondrogenesis via Direct Targeting to Smad1* , 2009, Journal of Biological Chemistry.
[9] S. Vatner,et al. Downregulation of MiR-199a Derepresses Hypoxia-Inducible Factor-1α and Sirtuin 1 and Recapitulates Hypoxia Preconditioning in Cardiac Myocytes , 2009, Circulation research.
[10] Yi Tie,et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.
[11] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[12] R. Poon,et al. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. , 2009, Cancer letters.
[13] P. Comoglio,et al. MicroRNAs impair MET-mediated invasive growth. , 2008, Cancer research.
[14] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[15] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[16] R. Pochampally,et al. Human multipotent stromal cells from bone marrow and microRNA: Regulation of differentiation and leukemia inhibitory factor expression , 2008, Proceedings of the National Academy of Sciences.
[17] C. Croce,et al. MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.
[18] C. Croce,et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.
[19] Derek Y. Chiang,et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.
[20] J. Dufour,et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. , 2008, Journal of hepatology.
[21] Ji Young Kim,et al. MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2)* , 2008, Journal of Biological Chemistry.
[22] Laura Pelletier,et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations , 2008, Hepatology.
[23] H. Huynh,et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.
[24] J. Nemunaitis,et al. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? , 2008, Cancer Gene Therapy.
[25] Krista A. Zanetti,et al. Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.
[26] Thomas D. Schmittgen,et al. Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival , 2008, Clinical Cancer Research.
[27] S. Giulini,et al. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. , 2007, International journal of oncology.
[28] A. Tee,et al. Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif* , 2007, Journal of Biological Chemistry.
[29] C. Croce,et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.
[30] C. Sander,et al. A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.
[31] Shelly C. Lu,et al. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density‐dependent in HepG2 cells , 2007, Journal of cellular physiology.
[32] S. Baksh,et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance , 2007, Molecular Cancer.
[33] J. Ajani,et al. Molecular mechanisms in cancer: what should clinicians know? , 2005, Seminars in oncology.
[34] E. Raymond,et al. mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] H. Lane,et al. The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.
[36] S. Kawasaki,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.
[37] L. Trusolino,et al. Invasive growth: from development to metastasis. , 2002, The Journal of clinical investigation.
[38] G. Thomas,et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.
[39] H. Edmondson,et al. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.
[40] C. Croce,et al. MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.
[41] H. Lane,et al. The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation , 2005 .